0.4998

15.11% 0.0656

After Hours: .49 -0.0098 -1.96%

Actuate Therapeutics Inc (ACTU)

Overview News Price History Financials Discussions Forecast

Actuate Therapeutics Inc stock is traded at $0.4998, with a volume of 455.25K. It is up +15.11% in the last 24 hours and down -49.19% over the past month. Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Previous Close:

$0.4342

Open:

$0.457

24h Volume:

455.25K

Relative Volume:

1.11

Market Cap:

$12.00M

Revenue:

Net Income/Loss:

$-21.54M

P/E Ratio:

-0.5046

EPS:

-0.9904

Net Cash Flow:

$-19.60M

1W Performance:

-26.39%

1M Performance:

-49.19%

6M Performance:

-76.75%

1Y Performance:

-93.62%

1-Day Range:

$0.4326

$0.55

1-Week Range:

$0.41

$0.6801

52-Week Range:

$0.41

$8.2652

Actuate Therapeutics Inc Stock (ACTU) Company Profile

Name

Actuate Therapeutics Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

847-986-4190

Address

1751 RIVER RUN, FORT WORTH

Employee

Twitter

Next Earnings Date

2026-11-12

Latest SEC Filings

ACTU's Discussions on Twitter

Compare ACTU vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACTU Actuate Therapeutics Inc	0.4998	12.00M	0	-21.54M	-19.60M	-0.9904
VRTX Vertex Pharmaceuticals Inc	508.74	128.95B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	236.50	94.42B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	796.35	81.99B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.50	53.23B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	374.30	42.34B	5.76B	514.49M	1.10B	4.4813

Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-26-25	Initiated	B. Riley Securities	Buy
Apr-22-25	Initiated	Craig Hallum	Buy
Mar-17-25	Initiated	H.C. Wainwright	Buy

Actuate Therapeutics Inc Stock (ACTU) Latest News

Oct 08, 2026

AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer - Zacks Investment Research

Oct 08, 2026

Oct 06, 2026

Actuate Therapeutics to sell 50 million shares at assumed $0.819 price - scanx.trade

Oct 06, 2026

Actuate Therapeutics Registers 50 Million Shares for Public Offering at $0.819 Each - Kalkine Media

Oct 06, 2026

At an assumed $0.819 a share, Actuate Therapeutics (Nasdaq: ACTU) proposes a stock offering. - Stock Titan

Oct 06, 2026

Sep 17, 2026

Gyre Therapeutics, Inc.Common Stock (Nasdaq:GYRE) Stock Quote - The Chronicle-Journal

Sep 17, 2026

Sep 09, 2026

Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire

Sep 09, 2026

Actuate Therapeutics Reports Synergistic Preclinical Activity of Elraglusib with RAS-Targeted Agents in Pancreatic Cancer Models - Quiver Quantitative

Sep 09, 2026

Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance

Sep 09, 2026

Sep 02, 2026

All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy - Yahoo Finance

Sep 02, 2026

Aug 21, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm

Aug 21, 2026

Aug 20, 2026

Actuate (ACTU) Results Check: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Closing Reaction: The Stock Gains 16.04% for the Current SessionInvestor Earnings Call - vinanet.vn

Aug 20, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Aug 20, 2026

Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move: Shares Move 0.95% Up at the CloseRevenue Estimate Trend - vinanet.vn

Aug 20, 2026

Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move - dars.gov.et

Aug 20, 2026

Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move - careplusvn.com

Aug 20, 2026

Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move: Shares Move 0.95% Up at the CloseEarnings Recovery Stocks - dars.gov.et

Aug 20, 2026

Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move - dars.gov.et

Aug 20, 2026

Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move: Shares Move 0.95% Up at the CloseSurprise Factor Analysis - dars.gov.et

Aug 20, 2026

Actuate (ACTU) Results Check: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Closing Reaction: The Stock Gains 16.04% for the Current SessionEarnings Revision Downgrade - https://www.dars.gov.et/

Aug 20, 2026

Aug 18, 2026

Actuate Therapeutics (ACTU) Holds $1.00 After 1.31% Gain, Pinned Between Key Support and ResistanceBullish Percent Index - vinanet.vn

Aug 18, 2026

Actuate Therapeutics stock gets FDA clearance for elraglusib trial By Investing.com - Investing.com Canada

Aug 18, 2026

Actuate Therapeutics (ACTU) Holds $1.00 After 1.31% Gain, Pinned Between Key Support and ResistanceInverse ETF Flow - dars.gov.et

Aug 18, 2026

Aug 16, 2026

Actuate Therapeutics (ACTU) Gains 3.58% to $1.01, Approaches Key Resistance at $1.06Bullish Pattern Stocks - vinanet.vn

Aug 16, 2026